Chronic lymphocytic leukemia: new concepts and emerging therapies.
Remarkable progress in elucidating the biology of chronic lymphocytic leukemia (CLL) has been made over the last two decades. Improved understanding of CLL has lead to new prognostic tools and therapeutic options, and holds promise for eventually finding a cure for this disease. Challenges lie in incorporating the various treatment modalities, including chemotherapy, monoclonal antibodies, immunotherapeutic strategies and novel small molecules, into a comprehensive treatment strategy guided by the biological complexity of CLL.
Ahmadi
Tahamtan
T
Hematologic Malignancies Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
Maniar
Tapan
T
Schuster
Stephen
S
Stadtmauer
Edward
E
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016175:B-Lymphocyte Subsets / Q000473:pathology; D000069461:Bendamustine Hydrochloride; D018956:CD5 Antigens / Q000032:analysis; D018450:Disease Progression; D015507:Drugs, Investigational / Q000627:therapeutic use; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy / Q000379:methods*; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000188:drug therapy / Q000235:genetics / Q000601:surgery / Q000628:therapy*; D015337:Multicenter Studies as Topic; D018365:Neoplasm, Residual; D009588:Nitrogen Mustard Compounds / Q000627:therapeutic use; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic / Q000706:statistics & numerical data; D016879:Salvage Therapy
D000911:Antibodies, Monoclonal; D018956:CD5 Antigens; D015507:Drugs, Investigational; D007155:Immunologic Factors; D009588:Nitrogen Mustard Compounds; D000069461:Bendamustine Hydrochloride